Related references
Note: Only part of the references are listed.Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
N. Kemeny et al.
ANNALS OF ONCOLOGY (2009)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
EMT, the cytoskeleton, and cancer cell invasion
Mahmut Yilmaz et al.
CANCER AND METASTASIS REVIEWS (2009)
Stabilization of Snail by NF-κB Is Required for Inflammation-Induced Cell Migration and Invasion
Yadi Wu et al.
CANCER CELL (2009)
Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth
Kei Sakamoto et al.
CLINICAL CANCER RESEARCH (2009)
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer
F. Caponigro et al.
EUROPEAN JOURNAL OF CANCER (2009)
Ikappa B Kinaseβ/Nuclear Factor-κB Activation Controls the Development of Liver Metastasis by Way of Interleukin-6 Expression
Shin Maeda et al.
HEPATOLOGY (2009)
Effectiveness of IκB kinase inhibitors in murine colitis-associated tumorigenesis
Yoku Hayakawa et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Sunhwa Kim et al.
NATURE (2009)
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
F. Graziano et al.
PHARMACOGENOMICS JOURNAL (2009)
Inflammation and cancer: Role of nuclear factor-kappaB activation
Shin Maeda et al.
CANCER SCIENCE (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Marwan Fakih
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
NF-κB in inflammatory bowel disease
I. Atreya et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Chemokines in tumor angiogenesis and metastasis
Seema Singh et al.
CANCER AND METASTASIS REVIEWS (2007)
New approaches in angiogenic targeting for colorectal cancer
Aleix Prat et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Combining chemotherapy and targeted therapies in metastatic colorectal cancer
J. Rodriguez et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis
Eugene Varfolomeev et al.
CELL (2007)
Cutting edge:: The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis
Wataru Shibata et al.
JOURNAL OF IMMUNOLOGY (2007)
Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo
Jing Yu et al.
GYNECOLOGIC ONCOLOGY (2007)
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products
Ajaikumar B. Kunnumakkara et al.
CANCER RESEARCH (2007)
MCP-1 mediates TGF-β-induced angiogenesis by stimulating vascular smooth muscle cell migration
Jing Ma et al.
BLOOD (2007)
Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: A clinical experience
Pochi R. Subbarayan et al.
ACTA ONCOLOGICA (2007)
Loss of Ikkβ promotes migration and proliferation of mouse embryo fibroblast cells
Fei Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Inflammation and cancer: How hot is the link?
Bharat B. Aggarwal et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Recent developments in colorectal cancer treatment by monoclonal antibodies
Dominique Arsene et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis
Kyoya Sakimura et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2006)
A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer
B Wang et al.
CANCER RESEARCH (2006)
A practical update on the use of bortezomib in the management of multiple myeloma
Jesus San Miguel et al.
ONCOLOGIST (2006)
5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
TP van Staa et al.
GUT (2005)
IKK/NF-κB signaling: balancing life and death -: a new approach to cancer therapy
JL Luo et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors
HB Zhu et al.
ONCOGENE (2005)
Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases
H Kamata et al.
CELL (2005)
Increased expression of the E3-ubiquitin ligase receptor subunit βTRCP1 relates to constitutive nuclear factor-κB activation and chemoresistance in pancreatic carcinoma cells
S Müerköster et al.
CANCER RESEARCH (2005)
CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A1
P Scapini et al.
JOURNAL OF IMMUNOLOGY (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer
FR Greten et al.
CELL (2004)
NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
MA Huber et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies
QSC Chu et al.
CLINICAL CANCER RESEARCH (2004)
The IKKNF-kappa B system: A treasure trove for drug development
M Karin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-κB-inducing kinase
P Ramakrishnan et al.
IMMUNITY (2004)
The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis
RC Bates et al.
EXPERIMENTAL CELL RESEARCH (2004)
TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling
C Becker et al.
IMMUNITY (2004)
Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
P Munkholm
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Regulation of cytokine signaling and inflammation
T Hanada et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Missing pieces in the NF-κB puzzle
S Ghosh et al.
CELL (2002)
Negative regulation of nuclear factor-κB activation and function by glucocorticoids
WY Almawi et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
Glucocorticoids: do we know how they work?
J Saklatvala
ARTHRITIS RESEARCH (2002)
Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling
E De Smaele et al.
NATURE (2001)
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
JA Eaden et al.
GUT (2001)
NF-κB and cell-cycle regulation:: the cyclin connection
D Joyce et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2001)
Nuclear factor-κB activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway
DZ Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition
QW Cheng et al.
ONCOGENE (2000)
Share Paper
